Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
about
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersPCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyondEconomic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics.Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Cholesterol Management in the Era of PCSK9 Inhibitors.Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.Alirocumab for the treatment of hypercholesterolaemia.Alirocumab for the treatment of hypercholesterolemia.Plaque imaging to refine indications for emerging lipid-lowering drugs.Bococizumab for the treatment of hypercholesterolaemia.Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen.Investigational therapies for hypercholesterolemia.Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up.Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them.Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies.Should we implement population screening for fragile X?PCSK9 Inhibitors Show Value for Patients and the US Health Care System.Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
P2860
Q28070296-7436E2A7-0F09-4026-8089-A5814FC1F451Q33625574-A8DF25A9-43FA-4EC3-BC06-6FEAFEFAED70Q33638980-3ABBF8B4-861C-4BC3-AA9B-757BE6152F93Q36247530-64A6A991-1E78-4A88-B94C-05DD88027605Q36366067-E5314A65-6D06-437C-8409-2BC7549134BFQ37636912-7DA40EF8-2C7C-4CC0-B3E8-D6DCB12ACF8AQ37688760-47495E27-E2DB-496A-860D-65B0C283F91BQ37723246-4747963E-2380-44C1-82B7-59F1153A22DDQ38604404-11926E7D-83E1-4A1E-8B9F-4B61CF75AEFAQ38612448-2E0094B6-C73C-4529-9645-7BEF2C22FB76Q38639580-6CC0176C-07E4-4E40-AD11-CAE5FEB9D4D0Q38690757-047ECD7A-E5CB-4818-8962-406BF33ACEACQ38828773-B4D3774C-A3FD-4EDF-B855-AC5DFE2E8C74Q38843982-463A4E03-55B4-4F8F-9504-EAD56E76B15BQ38917894-90C22BD3-7B37-4B8D-8471-64319CB4E730Q39000038-383343BF-A8EF-4695-ABDD-D70936130BA5Q39035931-54DE5CF5-5677-4070-95C7-7668A83EC85FQ39179519-C48760CA-98C0-45F2-875A-35C7A0FFD5BEQ39215123-DEDAC333-B1EB-49F2-BEB4-089AB54815F1Q39237132-9F5069BF-BFD0-4444-B71C-40AF42392ADCQ39324079-FB6A95E4-C02C-4D0A-A9DF-AD70BAF61169Q39453691-1BE69877-96E6-4483-946C-11DC6490C91BQ39458225-3A5B6E68-C1B3-4DDA-9A4D-D6E433F9CBB5Q40069909-87DCB5D9-75F0-41B9-99CC-09B5A2BFDD53Q41301852-CB42E17F-DF47-416B-A919-0326456C9C4FQ41503652-0643EF1B-DE16-4C34-86B8-9510F6F60889Q41544724-16E76779-B36A-4E64-A273-98F6A4BA873DQ42157277-49368A3C-3C37-4050-A834-EDAFFD8D2378Q46077572-1A67C206-3B97-452B-9842-79DBD9C43401Q46098353-D5F1926B-E668-4AEE-A931-C515697B863BQ46363164-2B07C4F3-E18B-4D4D-AD52-091DE30D1641Q46505421-66238D83-6BBF-41F4-A72E-C567591287C3Q46532049-C450C14C-3B80-491A-94AF-E728EE9836AEQ46828082-C6DF16D1-968E-4423-BDB3-DB88015A5AB1Q47147962-490D9345-28E3-4F49-BE90-D5D2C9A9D06CQ47363893-318E7999-8B44-4831-85FD-D7DC9210A20FQ47392228-322B4A3E-B3B7-4001-BBED-D883103BC24EQ47404233-5E1AFEEB-01EA-4EA7-B3E5-55C24DA48584Q47587162-4DC27FF1-CA11-49B9-A93B-3A60E2620E10Q47648628-3A4F0777-58D0-4E8D-A06A-1EB3D59741C5
P2860
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@ast
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@en
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@nl
type
label
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@ast
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@en
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@nl
prefLabel
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@ast
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@en
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@nl
P2093
P921
P356
P1476
Cost-effectiveness of PCSK9 In ...... erotic Cardiovascular Disease.
@en
P2093
Andrew E Moran
Daniel A Ollendorf
David Guzman
Dhruv S Kazi
Jeffrey A Tice
Joanne Penko
Pamela G Coxson
Steven D Pearson
P304
P356
10.1001/JAMA.2016.11004
P407
P577
2016-08-01T00:00:00Z